AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 FEB 14 - (NewsRx.com & NewsRx.net) --
- by Michelle Marble, staff medical writer -- Oral mycobacterial heat-shock protein 65 (Hsp65) therapy for autoimmune diseases was evaluated by researchers in The Netherlands.
"Oral administration of antigen prior to disease induction has been shown to induce peripheral tolerance in several experimental autoimmune diseases," wrote P.M. Cobelens and colleagues, University of Utrecht. "However, the clinical benefit of pretreatment with antigens is limited. The aim of this study was to investigate whether adjuvant-induced arthritis (AIA) could be treated-by oral administration of mycobacterial heat-shock protein 65 (Hsp65) during ongoing disease."
Cobelens et al. published their study in the journal Arthritis and Rheumatism ("Treatment of adjuvant-induced arthritis by oral, administration of mycobacterial Hsp65 during disease," Arthritis Rheum, 2000;43(12):2694-2702).
The researchers induced AIA in Lewis rats by immunizing them with Mycobacterium tuberculosis in Freund's incomplete adjuvant. Eleven days after immunization, the rats were started on oral administration of Hsp65 in the presence or absence of soybean trypsin inhibitor (SBTI). Animals and their arthritis were monitored visually. Joint pathology was examined by X-rays.
"Oral treatment with Hsp65 during ongoing disease significantly reduced the activity of AIA," stated the authors. "However, treatment with Hsp65 was only successful when SBTI was co-administered to prevent breakdown of the Hsp65."
Radiological data from the study demonstrated a clear reduction of articular destruction in the joints of the experimental AIA animals as a result of the Hsp65/SBTI ...